Asad Haider
Stock Analyst at Goldman Sachs
(2.46)
# 2,456
Out of 4,981 analysts
8
Total ratings
100%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Initiates: Neutral | $38 | $32.18 | +18.09% | 1 | Sep 12, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $24.19 | +11.62% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $96.74 | +13.71% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $178.06 | -3.40% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $755.39 | +17.56% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $218.34 | -11.15% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $46.20 | +19.05% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $23.87 | +4.73% | 1 | Apr 8, 2025 |
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $32.18
Upside: +18.09%
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $24.19
Upside: +11.62%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $96.74
Upside: +13.71%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $178.06
Upside: -3.40%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $755.39
Upside: +17.56%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $218.34
Upside: -11.15%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $46.20
Upside: +19.05%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $23.87
Upside: +4.73%